Reuters logo
BRIEF-Microbix Biosystems says consulted with FDA to return its thrombolytic biologic drug to U.S. market
May 1, 2017 / 12:21 PM / 8 months ago

BRIEF-Microbix Biosystems says consulted with FDA to return its thrombolytic biologic drug to U.S. market

May 1 (Reuters) - Microbix Biosystems Inc

* Microbix Biosystems Inc - consulted with FDA regarding plans to return its thrombolytic biologic drug, kinlytic urokinase to U.S. market

* Microbix Biosystems Inc - already received expressions of interest to license or acquire kinlytic and to provide full funding for its re-launch program Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below